The regulator's review will determine whether the product meets Kenya's requirements for quality, safety and efficacy before any approval is granted.
By
Linet Owoko
Correspondent
Nation Media Group
The Pharmacy and Poisons Board (PPB) has begun reviewing an application to register Mounjaro, a booming once-weekly injectable diabetes drug, for use in Kenya.
The Pharmacy and Poisons Board (PPB) has strengthened pharmaceutical regulation to protect patients and improve access to safe,…
The new indication for Eli Lilly's drug is for people with Type 2 diabetes.
The Pharmacy and Poisons Board has called for stronger quality assurance, safety monitoring and scientific research to ensure…
As African countries strengthen regulatory and digital health systems, we should measure more than whether reporting platforms…
The economics behind Kenya’s pharmaceutical industry are shaping which medicines reach patients.
Obesity treatment drug Mounjaro has been prescribed more than 1.5 million times in the 10 months since its domestic launch,…
